CUE Biopharma Presents Updated Data on CUE-101 at SITC 2024
Introduction
BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today presented updated data from its Phase 1 dose escalation and expansion trial evaluating its lead oncology asset from the Immuno-STAT™ CUE-100 series, CUE-101, in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The data was presented in an oral session at the Society for Immunotherapy of Cancer’s 39th Annual Meeting (SITC 2024) being held in Houston, Texas and virtually November 6-10.
Discussion
CUE-101 is a promising asset in the fight against R/M HNSCC, a challenging and often deadly form of cancer. The updated data presented at SITC 2024 demonstrates the potential of this novel therapeutic biologic to effectively engage and modulate disease-specific T cells, providing hope for improved treatment outcomes for patients facing this devastating disease.
Impact on Individuals
For individuals facing R/M HNSCC, the potential of CUE-101 to offer a new treatment option represents a beacon of hope. The updated data presented by Cue Biopharma at SITC 2024 offers promising results that may translate to improved survival rates and quality of life for patients battling this aggressive form of cancer.
Impact on the World
The development of innovative therapeutic biologics like CUE-101 has the potential to revolutionize the treatment landscape for cancer and autoimmune diseases on a global scale. By selectively engaging and modulating disease-specific T cells, these novel approaches hold promise for more targeted and effective treatments, ultimately benefiting patients worldwide.
Conclusion
As Cue Biopharma continues to advance the development of CUE-101 and other assets in the Immuno-STAT™ CUE-100 series, the future looks promising for individuals battling cancer and autoimmune diseases. The updated data presented at SITC 2024 marks an important milestone in the quest for more effective and targeted treatment options, offering hope for improved outcomes and quality of life for patients around the world.
